Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Mendus AB

Market Cap 313M 33.29M 28.75M 26.5M 24.8M 46.48M 3.16B 47.2M 122M 1.54B 125M 122M 5.33B P/E Ratio 2026 *
-3.34x
P/E Ratio 2027 * -5.68x
Enterprise Value -8.42M -896K -774K -713K -668K -1.25M -85.18M -1.27M -3.28M -41.46M -3.36M -3.29M -144M EV / Sales 2026 *
-0.94x
EV / Sales 2027 * 0.52x
Free-Float
30.82%
Yield 2026 *
-
Yield 2027 * -
1 day-1.35%
1 week+0.59%
Current month-10.37%
1 month-15.98%
3 months+21.43%
6 months+3.87%
Current year-8.93%
1 week 4.9
Extreme 4.9
5.67
1 month 4.9
Extreme 4.9
6.09
Current year 3.86
Extreme 3.86
6.9
1 year 3.86
Extreme 3.86
10.98
3 years 3.86
Extreme 3.86
16.38
5 years 3.86
Extreme 3.86
126.8
10 years 3.86
Extreme 3.86
640
Manager TitleAgeSince
Chief Executive Officer 54 16/03/2021
Chief Executive Officer 76 13/12/2019
Director of Finance/CFO 60 28/02/2021
Director TitleAgeSince
Chairman 52 22/01/2021
Director/Board Member 64 01/01/2020
Director/Board Member 74 01/01/2013
Date Insider Type Main position Quantity % Market Cap.
28/02/22Buy

Chief Technology Officer

10,000 0.0050%
24/02/22Buy

Chief Financial Officer

10,000 0.0050%
24/02/22Buy

Chief Financial Officer

10,000 0.0050%
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+0.59%-21.42%-61.83% 33.29M
-0.35%+0.97%-15.96%-12.73% 43.03B
+3.11%+3.11%+274.29%+507.94% 32.71B
+0.22%-1.08%+14.03%-14.37% 30.29B
+1.62%-2.08%-4.36%+24.05% 29.4B
+4.09%+0.93%+10.83%+18.78% 25.08B
-1.63%+2.88%+53.73%+114.36% 13.35B
+1.14%+3.62% - - 13.54B
-0.40%-1.29%+6.06%+7.59% 12.97B
-0.74%-1.62%+105.71%+76.01% 12.11B
Average +0.57%+1.36%+46.99%+73.31% 21.25B
Weighted average by Cap. +1.05%+1.48%+54.93%+97.28%

Financials

2026 *2027 *
Net sales 8.95M 952K 823K 758K 710K 1.33M 90.52M 1.35M 3.49M 44.06M 3.57M 3.5M 153M 224M 23.89M 20.63M 19.01M 17.8M 33.35M 2.27B 33.87M 87.53M 1.11B 89.65M 87.75M 3.83B
Net income -163M -17.34M -14.98M -13.8M -12.92M -24.21M -1.65B -24.59M -63.54M -802M -65.08M -63.69M -2.78B -18.59M -1.98M -1.71M -1.57M -1.47M -2.76M -188M -2.8M -7.25M -91.51M -7.42M -7.27M -317M
Net Debt -321M -34.19M -29.53M -27.21M -25.47M -47.73M -3.25B -48.47M -125M -1.58B -128M -126M -5.48B -197M -20.96M -18.11M -16.68M -15.62M -29.27M -1.99B -29.72M -76.81M -970M -78.67M -77M -3.36B
Logo Mendus AB
Mendus AB (publ), formerly Immunicum AB, is a Sweden-based company that is engaged in the biopharmaceutical sector. The Company develops immunotherapy for therapeutic treatment of cancer and infectious diseases. The Company develops off-the-shelf, cell-based products that are immunogenic based on underlying allogeneic dendritic cell biology and which have the potential to activate the patient’s own immune system against cancer. The Company’s programs ilixadencel and DCP-001 are derived from healthy donor material and from Company's DCOne cell line, respectively. The Company develops ilixadencel to address the tumor burden of established tumors via intratumoral immune priming and DCP-001 as a cancer relapse vaccine, aimed at the reduction of tumor recurrence following initial treatment. Mendus has offices in Sweden and the Netherlands.
Employees
27
Date Price Change Volume
12/06/26 5.100 kr -1.35% 6,477
11/06/26 5.170 kr -0.19% 10,712
10/06/26 5.180 kr +1.57% 11,476
09/06/26 5.100 kr +1.80% 15,613
08/06/26 5.010 kr -1.18% 5,225
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
5.100SEK
Average target price
16.00SEK
Spread / Average Target
+213.73%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMU Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!